Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
By using our website, you agree to our use of cookies.
English 
Chinese
The West Blog
Latest Post
June 27, 2019
Industry Trends in Biologic Formulations
In 2018, we saw a record-setting year for new-molecular entity (NME) approvals (59) at the FDA1 versus 46 in 2017. 58% were for orphan drugs (patient population less than 200,000 in the US) with 17 biologic-based NME’s. Biosimilars are gaining traction in Europe, in particular. Major factors that are driving the market growth are next-generation business, high growth in chronic diseases, less expensive biosimilar drugs and favorable government regulations.
Previous Posts
